Scientific Sessions 2024  /  Featured Science: Incretin Modulation: Is a New Standard of Care Emerging?  /  Incretin Analogues for Addressing Multisystem Morbidity
Logo

American Heart Association

  16
  0

Final ID:

Incretin Analogues for Addressing Multisystem Morbidity

  • Neuen, Brendon  ( George Institute for Global Health , Newtown , New South Wales , Australia )
  • Ndumele, Chiadi  ( JOHNS HOPKINS HOSPITAL , Baltimore , Maryland , United States )
    • Author Disclosures:
    Brendon Neuen: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Menarini:Expected (by end of conference) ; Consultant:Travere Therapeutics:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Boehringer and Ingelheim:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Alexion:Active (exists now) | Chiadi Ndumele: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Incretin Modulation: Is a New Standard of Care Emerging?

Monday, 11/18/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Discussant: SUMMIT

Lewis Eldrin

Effects of Tirzepatide on the Clinical and Symptom Burden of Patients with Heart Failure and a Preserved Ejection Fraction, Results from the SUMMIT Trial

Zile Michael

More abstracts from these authors:
Cardiovascular Risk Prediction with the Kidney Failure Risk Equation Among Patients with Chronic Kidney Disease: Insights from CRIC

Correa Simon, Beldhuis Iris, Neuen Brendon, Vaduganathan Muthiah, Wilson F. Perry, Mc Causland Finnian

Overview of AHA CKM

Ndumele Chiadi

You have to be authorized to contact abstract author. Please, Login
Not Available